MA51688A - Protéines prohémostatiques pour le traitement de saignement - Google Patents

Protéines prohémostatiques pour le traitement de saignement

Info

Publication number
MA51688A
MA51688A MA051688A MA51688A MA51688A MA 51688 A MA51688 A MA 51688A MA 051688 A MA051688 A MA 051688A MA 51688 A MA51688 A MA 51688A MA 51688 A MA51688 A MA 51688A
Authority
MA
Morocco
Prior art keywords
bleeding
treatment
prohemostatic
proteins
prohemostatic proteins
Prior art date
Application number
MA051688A
Other languages
English (en)
Inventor
Mettine H A Bos
Pieter H Reitsma
Daniël Verhoef
Original Assignee
Academisch Ziekenhuis Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academisch Ziekenhuis Leiden filed Critical Academisch Ziekenhuis Leiden
Publication of MA51688A publication Critical patent/MA51688A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA051688A 2014-05-26 2015-05-26 Protéines prohémostatiques pour le traitement de saignement MA51688A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14169895 2014-05-26

Publications (1)

Publication Number Publication Date
MA51688A true MA51688A (fr) 2020-12-02

Family

ID=50774744

Family Applications (2)

Application Number Title Priority Date Filing Date
MA051688A MA51688A (fr) 2014-05-26 2015-05-26 Protéines prohémostatiques pour le traitement de saignement
MA40042A MA40042B1 (fr) 2014-05-26 2015-05-26 Protéines prohémostatiques pour le traitement de saignement

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA40042A MA40042B1 (fr) 2014-05-26 2015-05-26 Protéines prohémostatiques pour le traitement de saignement

Country Status (24)

Country Link
US (5) US10537618B2 (fr)
EP (2) EP3744840A1 (fr)
JP (3) JP6640198B2 (fr)
KR (2) KR102351728B1 (fr)
CN (1) CN106536566A (fr)
AU (2) AU2015268149B2 (fr)
CA (1) CA2949349A1 (fr)
DK (1) DK3149163T3 (fr)
EA (2) EA202190813A1 (fr)
ES (1) ES2813440T3 (fr)
HR (1) HRP20201311T1 (fr)
HU (1) HUE052098T2 (fr)
IL (2) IL249132B (fr)
LT (1) LT3149163T (fr)
MA (2) MA51688A (fr)
MX (2) MX378899B (fr)
NZ (1) NZ727444A (fr)
PL (1) PL3149163T3 (fr)
PT (1) PT3149163T (fr)
RS (1) RS60706B1 (fr)
SG (2) SG10201906329VA (fr)
SI (1) SI3149163T1 (fr)
WO (1) WO2015183085A1 (fr)
ZA (1) ZA201608017B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3744840A1 (fr) 2014-05-26 2020-12-02 Academisch Ziekenhuis Leiden Protéines prohémostatiques pour le traitement de saignement
CN108486197B (zh) * 2018-03-06 2021-10-22 爱斯特（成都）生物制药股份有限公司 高纯度依度沙班中间体的制备方法
GB202408056D0 (en) * 2024-06-06 2024-07-24 Cambridge Entpr Ltd Anticoagulant protein molecules and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
EP0785273A1 (fr) 1990-11-26 1997-07-23 Genetics Institute, Inc. Enzyme de conversion d'acides aminés basiques couplés et séquence d'ADN codant pour cette enzyme
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
DE4203965A1 (de) 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren
AT404357B (de) 1995-06-13 1998-11-25 Immuno Ag Prothrombin-derivate
DE19605126A1 (de) 1996-02-12 1997-08-14 Basf Ag Thrombinmuteine als Antidot für Thrombininhibitoren
US6200955B1 (en) 1996-06-11 2001-03-13 Commonwealth Biotechnologies, Inc. Heparin binding peptides
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
EP1728798A1 (fr) 2005-06-01 2006-12-06 ZLB Behring GmbH Polypeptides du facteur X de la coagulation avec propiertés d'activation modifiées
MX2008006313A (es) * 2005-11-15 2008-11-06 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
EP1820508A1 (fr) * 2006-02-21 2007-08-22 CSL Behring GmbH Polypeptides du facteur de coagulation X avec des propriétés d'activation modifiées
WO2008127702A2 (fr) * 2007-04-13 2008-10-23 Catalyst Biosciences, Inc. Polypeptides du facteur vii modifiés et leurs utilisations
BRPI0816837B1 (pt) 2007-09-28 2022-10-18 Portola Pharmaceuticals, Inc Composições farmacêuticas, polipeptídeo isolado de duas cadeias e uso de uma composição farmacêutica
TWI465247B (zh) * 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
PT2453910T (pt) 2009-07-15 2016-12-07 Portola Pharm Inc Formulação de dose unitária de antídoto contra inibidores de fator xa para uso na prevenção de sangramento
US9145552B2 (en) 2012-07-25 2015-09-29 Catalyst Biosciences, Inc. Modified factor X polypeptides and uses thereof
EP2950813B1 (fr) 2013-01-31 2019-09-04 Pfizer Inc Compositions et procédés pour contrer l'inhibition du facteur xa
US10119101B2 (en) 2014-04-28 2018-11-06 Ecolab Usa Inc. Method of minimizing enzyme based aerosol mist using a pressure spray system
EP3744840A1 (fr) * 2014-05-26 2020-12-02 Academisch Ziekenhuis Leiden Protéines prohémostatiques pour le traitement de saignement

Also Published As

Publication number Publication date
US20240390467A1 (en) 2024-11-28
US20200138916A1 (en) 2020-05-07
DK3149163T3 (da) 2020-08-31
MA40042B1 (fr) 2020-08-31
IL249132A0 (en) 2017-01-31
SI3149163T1 (sl) 2020-10-30
EP3744840A1 (fr) 2020-12-02
MX378899B (es) 2025-03-10
SG11201609811TA (en) 2016-12-29
JP2020062039A (ja) 2020-04-23
JP7535849B2 (ja) 2024-08-19
JP6640198B2 (ja) 2020-02-05
JP2022134139A (ja) 2022-09-14
US12083170B2 (en) 2024-09-10
IL277377A (en) 2020-11-30
AU2015268149A1 (en) 2016-12-08
JP2017522900A (ja) 2017-08-17
EA201692161A1 (ru) 2017-08-31
US11357836B2 (en) 2022-06-14
US20200138917A1 (en) 2020-05-07
SG10201906329VA (en) 2019-08-27
EP3149163B1 (fr) 2020-06-03
MX2020013410A (es) 2021-02-26
AU2015268149B2 (en) 2021-03-11
HUE052098T2 (hu) 2021-04-28
AU2021203838B2 (en) 2023-03-02
US20170157223A1 (en) 2017-06-08
PT3149163T (pt) 2020-09-03
WO2015183085A1 (fr) 2015-12-03
EA202190813A1 (ru) 2021-12-31
AU2021203838A1 (en) 2021-07-08
CA2949349A1 (fr) 2015-12-03
US10537618B2 (en) 2020-01-21
US20220288172A1 (en) 2022-09-15
LT3149163T (lt) 2020-09-25
ZA201608017B (en) 2019-04-24
ES2813440T3 (es) 2021-03-23
IL277377B (en) 2021-10-31
EP3149163A1 (fr) 2017-04-05
EA037991B1 (ru) 2021-06-21
NZ764611A (en) 2024-07-05
KR102351728B1 (ko) 2022-01-14
KR20170020332A (ko) 2017-02-22
HRP20201311T1 (hr) 2020-12-11
KR102245264B1 (ko) 2021-04-28
NZ727444A (en) 2021-12-24
MX2016015567A (es) 2017-06-29
PL3149163T3 (pl) 2020-12-28
RS60706B1 (sr) 2020-09-30
US11304995B2 (en) 2022-04-19
KR20210054573A (ko) 2021-05-13
BR112016027649A2 (pt) 2017-08-15
IL249132B (en) 2020-09-30
CN106536566A (zh) 2017-03-22

Similar Documents

Publication Publication Date Title
MA47719A (fr) Esketamine pour le traitement de la dépression
MA39748A (fr) Cenicriviroc pour le traitement de la fibrose
EP3388004A4 (fr) Instrument de traitement
MA41449A (fr) Polythérapies pour le traitement de cancers
EP3374502A4 (fr) Procédés pour le traitement de dystrophies cornéennes
HUE057817T2 (hu) Anti-LAG-3 antitestek haematológiai malignitások kezelésére
HUE059158T2 (hu) Eljárás pridopidin elõállítására
EP3504187A4 (fr) Utilisation de la pridopidine pour le traitement du déclin fonctionnel
MA42999A (fr) Polythérapie pour le traitement de malignités
EP3288592A4 (fr) Utilisation de cannabidiol pour le traitement de spasmes infantiles
EP3380200A4 (fr) Compositions pour le traitement des cheveux
EP3351189A4 (fr) Instrument de traitement pour endoscope
EP3389645A4 (fr) Combinaisons pour le traitement du cancer
EP3335041A4 (fr) Biomarqueurs pour le traitement de la pelade
EP3400011A4 (fr) Combinaisons anti-cd20 pour le traitement des tumeurs
EP3359255A4 (fr) Polythérapies pour le traitement du cancer
EP3380063A4 (fr) Compositions pour le traitement des cheveux
EP3375108A4 (fr) Traitement dewlan
EP3490561A4 (fr) Combinaisons pour le traitement du cancer
EP3334432A4 (fr) Cerdulatinib pour le traitement du myélome
EP3316887A4 (fr) Inhibiteurs de gls1 pour le traitement de maladies
EP3386967A4 (fr) Combinaisons pour le traitement de calculs rénaux
EP3349793A4 (fr) Anti-s100a8 pour le traitement de la leucémie
EP3318205A4 (fr) Instrument de traitement pour endoscope
EP3503887A4 (fr) Combinaisons pour le traitement du cancer